Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
about
UK guidelines for the management of soft tissue sarcomasThe evolution of systemic therapy in sarcoma.Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumorsColony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.Emerging therapies for adult soft tissue sarcoma.Current treatment options for dermatofibrosarcoma protuberans.[Synovial tumors and tumor-like lesions].Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.Advances in sarcoma genomics and new therapeutic targets.New systemic therapy options for advanced sarcomas.Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumorsMolecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowResponse to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinibSilk constructs for delivery of musculoskeletal therapeutics.Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma.Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.Arthroscopic synovectomy in pigmented villonodular synovitis of the knee: clinical series and outcome.Targeted therapies: the rare cancer paradigm.Targeted therapy for sarcomas.Imatinib mesylate for the treatment of gastrointestinal stromal tumor.Nilotinib: a novel, selective tyrosine kinase inhibitor.Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.Pigmented villonodular synovitis: current concepts about diagnosis and management.Pigmented villonodular synovitis of the temporomandibular joint with intracranial extension: A case series and systematic review.Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors.Pigmented villonodular synovitis responsive to imatinib therapyTherapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.CSF-1R Inhibitor Development: Current Clinical Status.Extra-articular diffuse-type tenosynovial giant cell tumor with benign histological features resulting in fatal pulmonary metastases.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.
P2860
Q28076730-B7F98D05-0D38-45C3-A785-10591E1928B7Q33274710-6A2FF271-BFE6-445D-9FC8-B18D746CD08FQ33636985-5E5165B0-3B72-408E-944D-7A23733C1F5EQ33912938-CCACD868-0A9F-440A-8C9E-6AF6048D52DDQ34023059-938BD96C-487F-4445-979C-A67D6DB2F40BQ34578454-BAC4175C-FCE0-49D5-841E-DAAF5686D0AAQ34659806-4442BEC3-D89B-4ED6-9BA3-D1E1674C957EQ34670080-458E1D97-D9AD-4C9F-9E2B-837AED9E7F95Q34673094-048F3BC6-757C-487D-8F5E-6807E4786B18Q35894526-F6685867-96A2-46F0-831E-279F7419C029Q35993346-0AAF3A49-C451-4509-979D-2852FBE09775Q36166394-016BCC6F-6EE8-4EE6-9967-D4D2CABD01CBQ36475866-2A4EF66B-7ECA-4B92-A9CC-AC270AEC2A88Q36819466-BDB547C3-F211-42F7-B0A3-28D8348259ABQ36866959-7E8DD18C-71EA-44B0-BC35-110A354272EAQ37035579-573A011C-975B-4ACE-A935-3D4585B723E4Q37197412-E78AAA7F-6D6F-4760-B7EA-F5A5CABB6698Q37278365-90896C1D-F0AF-4AD1-833A-4E8E3C3D72CFQ37349355-C4284BA5-C67B-432E-B305-EAFF91839FC8Q37632825-5D0B019A-8DE2-47F4-8590-05C8F88CC0C8Q37655450-2AE6D8FA-5B9F-42CA-ABCB-3675C6DAEEF9Q37752353-16EC207D-8111-498B-9704-27E98E3BF6A2Q37855073-AD0256CB-BEBA-472A-878C-6ABEE7BDE57FQ38011606-C7C921BC-65D9-4253-AB04-8A448DB8CB23Q38027107-0CBBDDAB-C90F-4499-9AB7-565EDD25CE94Q38150874-55BBD92B-47E7-4638-B704-E27D513DB53AQ38206988-5D20D5D0-50D4-4E9D-ADBE-E6D62914C92DQ38714796-1890F5AE-4E21-4F2D-8AEC-83F78947E1FEQ39743562-51349E06-3C8E-4914-8E44-85E1EC30C6EFQ40360842-60EAD6FA-8963-4DCA-B3EF-605FB1F0F301Q41855916-4F5B2E13-A7C2-4060-A511-176C87769696Q42408332-BA301746-29F9-4A3C-AC06-5805DE9998F1Q42726968-F2085C4A-A689-4F0F-8147-6BABC53AB92EQ47963731-30D3154A-2B25-4395-8E06-5405C4EC2D6BQ47969440-DF1B483A-2CA7-4A8C-905A-92EA93FC15E2Q48290538-AA9FF657-4666-4633-9947-7E963CC79883Q50709731-B75CB1B0-9249-4815-B4EF-9F3D5BC269E1Q54569245-9686CD4B-DD1B-4BCF-B88D-BC868DE0D6E0Q54645672-E9ECA30B-86F1-4B46-9B4F-5843F241F5BBQ55092685-42D5C3D5-88C3-4698-A6B3-1783E1BCFE2A
P2860
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Complete response to imatinib ...... giant cell tumor (PVNS/TGCT).
@en
Complete response to imatinib ...... /tenosynovial giant cell tumor
@nl
type
label
Complete response to imatinib ...... giant cell tumor (PVNS/TGCT).
@en
Complete response to imatinib ...... /tenosynovial giant cell tumor
@nl
prefLabel
Complete response to imatinib ...... giant cell tumor (PVNS/TGCT).
@en
Complete response to imatinib ...... /tenosynovial giant cell tumor
@nl
P2093
P356
P1433
P1476
Complete response to imatinib ...... giant cell tumor (PVNS/TGCT).
@en
P2093
H El Sayadi
I Ray-Coquard
P304
P356
10.1093/ANNONC/MDN033
P577
2008-02-21T00:00:00Z